• Home
  • Adalvo Limited

Adalvo Limited

About Adalvo Limited

Adalvo is a leading B2B pharmaceutical company in Europe with over 110 global partners in 100+ countries. The company's goal is to improve patient care by providing high-quality products and services through a smart collaboration network. Adalvo's unique approach is tailored to each partner, helping them grow their business and achieve their objectives, whether that's increasing revenue or expanding into new markets. The company also prioritizes employee development and community growth while striving for excellence. Adalvo's commitment to excellence and making a difference ensures tha...

Read more Show less
Certifications
  • GMP
    GMP
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • MT
  • 2020
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
Other
Primary activities
Out-licensing specialist
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Frankfurt 2025

Messe, Frankfurt
28 Oct 2025 - 30 Oct 2025
View Exhibitor Profile

Adalvo Limited Resources (2)

  • Adalvo CEO, Anil Okay nominated as finalist for CEO of the year award

    News Adalvo CEO, Anil Okay nominated as finalist for CEO of the year award

    Adalvo are honored to have been recognized by CPhI Pharma, where our CEO, Anil Okay, has been nominated as a finalist for the CEO of the Year Award!

    27 Sep 2023
  • Adalvo announces successful DCP Submission for Desogestrel + Ethinylestradiol (0.15mg+0.02mg) film coated tablets

    Technical Data Adalvo announces successful DCP Submission for Desogestrel + Ethinylestradiol (0.15mg+0.02mg) film coated tablets

    We are pleased to announce our successful DCP submission for Desogestrel+Ethinylestradiol (0.15mg+0.02mg) film-coated tablets.

    This accomplishment enables Adalvo to provide multiple treatment options to both partners and patients.

    Our Desogestrel+Ethinylestradiol 0.15mg/0.02mg film-coated tablets were developed in collaboration with one of our strategic partners, based on the reference brand Mercilon film-coated tablets. The product is a low-dose contraceptive used by women to prevent pregnancy.

    According to IQVIA, Desogestrel+Ethinylestradiol (0.15mg+0.02mg) generated approximately $85mn in global sales in 2022.

    Building on this accomplishment, Adalvo continues to expand their Women's Health portfolio. As a distinguished player in this domain, we are delighted to offer a wide range of products, as outlined below:

    Cyproterone + Ethinylestradiol, 2 mg + 0.035 mgDesogestrel, 75 mcgDesogestrel +...